Add this copy of Treatment-Resistant Mood Disorders to cart. $119.75, new condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2001 by Cambridge University Press.
Add this copy of Treatment-Resistant Mood Disorders: Diagnosis and to cart. $2,346.50, new condition, Sold by BWS Bks rated 5.0 out of 5 stars, ships from Ferndale, NY, UNITED STATES, published 2001 by Cambridge Univ Pr.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. 0521593417. *** FREE UPGRADE to Courier/Priority Shipping Upon Request ***-*** IN STOCK AND IMMEDIATELY AVAILABLE FOR SHIPMENT-FLAWLESS COPY-AVAILABLE IMMEDIATELY, WHY WAIT? --552 pages--Choose us, for the information you need--DESCRIPTION: --Although antidepressants have helped millions worldwide, a substantial proportion of patients fail to respond or remit. There is little published information available to clinicians for diagnosis and management of treatment-resistant depression, causing them to make difficult decisions regarding treatment options with very limited data. The editors and their internationally distinguished team of contributors have set out to address this problem, giving a critical assessment of all aspects of treatment-resistant depression: causes, epidemiology, comorbidity, evaluation, and treatment. This timely book will be invaluable to clinicians, neuroscientists, researchers, and graduate students. --SYNOPSIS: --Contributors offer a critical assessment of all aspects of treatment-resistant mood disorders, addressing causes, epidemiology, comorbidity, evaluation, and treatment. The volume begins with chapters addressing the clinical problem of treatment-resistant mood disorders, followed by discussion of the biological basis, including the psychoneuroendocrine aspects, the role of estrogen for women, sleep abnormalities, structural and functional brain imaging, and immunologic factors. Next, various treatment approaches are covered, including SSRIs, drug combination strategies, thyroid augmentation, and cognitive therapy, and psychosocial interventions, among others. Special populations are then covered, followed by two final contributions addressing economic and ethical issues. Of likely interest to clinicians, neuroscientists, researchers, and graduate students. --Contributors: --Daniel Souery, Olivier Lipp, Julien Mendlewicz, Jeffrey S. McCombs, Glen L. Stimmel, Rita L. Hui, T. Jeffrey White, Owen M. Wolkowitz, Victor I. Reus, Barbara B. Sherwin, Anna Sluzewska, Janusz Rybakowski, Jay D. Amsterdam, Terence A. Ketter, Christopher J. Bench, Mark S. George, Tim A. Kembrell, Robert M. Post, Martin P. Szuba, Antonio T. Fernando, Geralyn Groh-Szuba, John P. OReardon, Lawrence H. Price, Linda L. Carpenter, Steven A. Rasmussen, William Boyer, Richard Bunt, Russell T. Joffe, David Bakish, Cynthia L. Hooper, Max Fink, Jan Scott, Robert J. DeRubeis, Adelita Segovia, Kelly N. Botteron, Barbara Geller, Paul A. Newhouse, Jaskaran Singh, Zachary N. Stowe, Pamela McCreary, Claudia Baugh, Alexis Llewellyn, Jonathan E. Alpert, Isabelle T. Lagomasino, Jan Fawcett, Paul Root Wolpe, Arthur Caplan, Mark A. Frye, Kirk D. Denicoff, Andrew Speer, Susan R. B. Weiss, Gabriele S. Leverich, Mady Hornig, Stanley S. Harris Sr, Amy Hostetter, Isabelle Massat--with a bonus offer--
